

Granules India Receives U.S. FDA Approval for its Naproxen Sodium ANDA

October 11, 2011

PRESS RELEASE

Hyderabad, October 11, 2011

Granules India Receives U.S. FDA Approval for its Naproxen Sodium ANDA

Granules India Ltd., (NSE: GRANULES, BSE: 532482) a vertically integrated formulation manufacturer, announced today, that the U.S. Food and Drug Administration (U.S. FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Naproxen Sodium 220mg.

Naproxen Sodium, a non-steroidal anti-inflammatory drug (NSAID), is used to reduce pain, fever and inflammation. The drug is sold under various brand names such as Aleve and Midol in the U.S. Annual sales for branded Naproxen Sodium tablets and caplets in the U.S. exceeded \$200 million for the twelve months ending March 31, 2011 according to SymphonyIRI Group.

Granules is in active discussions with several U.S. generics drug manufacturers and expects commercial orders for Naproxen Sodium Finished Dosages to commence in the first half of 2012.

Commenting on the approval, Mr. C. Krishna Prasad, Managing Director at Granules India, said, "We are pleased to receive this approval because it is another significant step in our effort of becoming the leading formulation manufacturer of high-volume products. Granules has highly efficient facilities that excel in large-scale manufacturing so we are excited to offer Naproxen Sodium which is used in more than six billion doses per year. We will build on our momentum by filing global applications for several more products in order to extend our market penetration."

About Granules India Ltd.

Granules is a world class, large scale manufacturing company partnering with market leaders to offer pharmaceutical products and services. We have a long history as a producer of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). Our integrated model allows us to provide products throughout the value chain in a cost-effective and efficient manner. We serve over 300 customers in 50 countries through our sales offices in India, U.S., U.K., Colombia and China.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.